Health Privacy in 2025 and Beyond

WilmerHale lawyer Ali Jessani recently authored the article “Health Privacy in 2025 and Beyond,” published by the American Bar Association.

Data Protection law in the United States has evolved rapidly over the past few years. The changes relating to health privacy have been particularly noteworthy. Gone are the days where companies only needed to worry about whether they fall under the purview of HIPAA. Now, almost all health data (as well as data that could potentially […]

By | Apr 03, 2025 ||

Navigating Medicaid Drug Rebate Program (MDRP) Compliance: A Guide For Pharmaceutical Manufacturers

The Medicaid Drug Rebate Program (MDRP) is a cornerstone of pharmaceutical pricing regulation, requiring drug manufacturers to provide rebates to Medicaid in exchange for coverage of their products. Established under the Omnibus Budget Reconciliation Act of 1990 (OBRA ’90) and administered by the Centers for Medicare & Medicaid Services (CMS), the MDRP ensures Medicaid programs pay competitive prices for prescription drugs while presenting compliance challenges for manufacturers.

Given the strict reporting requirements, complex rebate calculations, […]

By | Apr 01, 2025 ||

States Continue To Pursue And Expand Healthcare Market Oversight, With Significant Implications For Private Equity

In recent years, states have shown an increased interest in regulating healthcare markets. The trend has accelerated further since the start of 2025, with a flurry of proposals in at least 12 states. Some of these proposed laws specifically aim to regulate private equity investment in healthcare, and all of these draft laws would profoundly affect the way private equity currently does business if passed in their current form. For regulated parties, this increase […]

By | Mar 30, 2025 ||